Project Grant R37CA292843
Award Date
8/28/24
Completion Date
7/31/29
Dollars Obligated
$351K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Miami, FL 33136, USA
Similar Awards
This federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower program) totaling $107,948 aims to develop an immunotherapy approach for treating pancreatic cancer using micro-RNA-29a. The key objectives are to: 1) Alter the differentiation of terminally exhausted T cells to a progenitor and memory-like phenotype that is responsive to immune checkpoint blockade therapy, and 2) Determine the contribution of myeloid-derived TNF-TNFR2 signaling to T...
This $578,998 Project Grant award from the National Cancer Institute (under CFDA 93.395 - Cancer Treatment Research) aims to develop a novel targeted therapeutic strategy against metastatic pancreatic ductal adenocarcinoma (PDAC). The key objectives are to:
Determine the mechanisms by which the cancer-specific Tn antigen enhances PDAC tumor progression and identify Tn-expressing glycoproteins through advanced glycoproteomics analysis in mouse models and clinical samples.
Validate the role...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $453,304 to The University of Texas MD Anderson Cancer Center to conduct research on defining pro-metastatic drivers in the pancreatic cancer tumor microenvironment. The key objectives are to gain mechanistic insights into how p53 mutations in tumor cells drive pro-metastatic interactions with cancer-associated fibroblasts, and to test if disrupting the mutant p53/CREB1 complex...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $674,275 to Marker Therapeutics Inc., a self-certified small disadvantaged biotechnology company, to conduct a Phase 1 clinical study evaluating the safety and efficacy of their MT-601 multi-tumor associated antigen-specific T-cell therapy in combination with frontline chemotherapy (FOLFIRINOX) for the treatment of metastatic pancreatic cancer. The study aims to assess the primary...
This $151,912 Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research at the Medical College of Wisconsin (MCW) to characterize the role of CCR6+ regulatory T cells (Tregs) in pancreatic cancer immunosuppression. The key objectives are to:
Use in vitro assays to determine if CCR6+ Tregs exhibit increased immunosuppressive capabilities compared to CCR6- Tregs, and assess the effects of the CCR6 ligand CCL20 on Treg...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding for research aimed at developing an innovative protein drug called PROAGIO to simultaneously target cancer-associated fibroblasts (CAFs) and abnormal tumor blood vessels in pancreatic ductal adenocarcinoma (PDAC). The $590,094 award to the University of Alabama at Birmingham (UAB) will support a Phase I clinical trial to evaluate the safety, pharmacokinetics, and preliminary...
This $192,240 Project Grant awarded by the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) will support research conducted by the University of Texas MD Anderson Cancer Center to investigate the functional contribution of cancer cell-derived extracellular vesicles (CCEVs) in pancreatic cancer initiation, progression, and metastasis. The research program aims to track the transfer and functional impact of CCEVs on the tumor microenvironment using novel mouse models....
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research to characterize the role of mesothelial cell-derived cancer-associated fibroblasts (CAFs) in pancreatic ductal adenocarcinoma (PDA). The central hypothesis is that mesothelial cells give rise to a distinct, immunomodulatory population of CAFs in PDA. The $139,445 award, effective September 18, 2024 through August 31, 2028, will enable in vivo and in vitro studies to (1)...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $421,685 to The University of Texas Southwestern Medical Center to investigate the therapeutic potential of inhibiting the protein pleiotrophin (PTN) to combat pancreatic cancer metastasis. The 2-year project aims to determine if blocking PTN, which is associated with pancreatic cancer progression, can reduce metastasis and enhance the effectiveness of chemotherapy and...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research by The Institute for Cancer Research to investigate the role of the protein Anoctamin 6 (ANO6) in disrupting lipid transfer between cancer-associated fibroblasts and pancreatic cancer cells. The $642,755 award, which commenced on March 7, 2025 and is scheduled for completion by February 28, 2030, aims to:
Delineate the signaling mechanisms by which cancer cells induce...